The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | A real-world study evaluating combined modality therapy for early-stage Hodgkin lymphoma
Karan Chohan, MD, Mayo Clinic, Rochester, MN, gives an overview of a real-world study which evaluated combined modality therapy in patients with Hodgkin lymphoma (HL), highlighting the improved progression-free survival (PFS) observed in these patients, and further comments on the value of real-world data in this setting. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
